Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 56

1.

Effect of psychological distress on continuation of anti-tumor necrosis factor therapy in patients with rheumatoid arthritis.

Mattey DL, Dawes PT, Hassell AB, Brownfield A, Packham JC.

J Rheumatol. 2010 Oct;37(10):2021-4. doi: 10.3899/jrheum.100050. Epub 2010 Aug 3.

PMID:
20682674
2.

Relationship between pack-year history of smoking and response to tumor necrosis factor antagonists in patients with rheumatoid arthritis.

Mattey DL, Brownfield A, Dawes PT.

J Rheumatol. 2009 Jun;36(6):1180-7. doi: 10.3899/jrheum.081096. Epub 2009 May 15.

PMID:
19447930
3.
4.

Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

Hyrich KL, Watson KD, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register..

Rheumatology (Oxford). 2006 Dec;45(12):1558-65. Epub 2006 May 16.

PMID:
16705046
5.

Health-related quality of life and continuation rate on first-line anti-tumour necrosis factor therapy among rheumatoid arthritis patients from the Australian Rheumatology Association Database.

Staples MP, March L, Lassere M, Reid C, Buchbinder R.

Rheumatology (Oxford). 2011 Jan;50(1):166-75. doi: 10.1093/rheumatology/keq322. Epub 2010 Oct 7.

PMID:
20929971
6.

Anti-tumor necrosis factor-alpha therapy in the ordinary clinical setting: Three-year effectiveness in patients with rheumatoid arthritis.

Kvalvik AG, Lefsaker L, Dyvik S, Brun JG.

Joint Bone Spine. 2007 Dec;74(6):606-11. Epub 2007 Aug 9.

PMID:
17900958
7.

Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis.

Braun-Moscovici Y, Markovits D, Zinder O, Schapira D, Rozin A, Ehrenburg M, Dain L, Hoffer E, Nahir AM, Balbir-Gurman A.

J Rheumatol. 2006 Mar;33(3):497-500.

PMID:
16511906
8.

Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy.

Mäki-Petäjä KM, Hall FC, Booth AD, Wallace SM, Yasmin, Bearcroft PW, Harish S, Furlong A, McEniery CM, Brown J, Wilkinson IB.

Circulation. 2006 Sep 12;114(11):1185-92. Epub 2006 Sep 4.

9.

Depression in RA patients treated with anti-TNF is common and under-recognized in the rheumatology clinic.

Hider SL, Tanveer W, Brownfield A, Mattey DL, Packham JC.

Rheumatology (Oxford). 2009 Sep;48(9):1152-4. doi: 10.1093/rheumatology/kep170. Epub 2009 Jul 16.

PMID:
19608723
10.
11.

Psychometric properties of the Rheumatoid Arthritis Disease Activity Index (RADAI) in a cohort of consecutive Dutch patients with RA starting anti-tumour necrosis factor treatment.

Veehof MM, ten Klooster PM, Taal E, van Riel PL, van de Laar MA.

Ann Rheum Dis. 2008 Jun;67(6):789-93. Epub 2007 Nov 1.

PMID:
17974597
13.

The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug: comments on the article by Söderlin et al.

Park SJ, Shin JI.

Scand J Rheumatol. 2012 Oct;41(5):411-2. doi: 10.3109/03009742.2012.698394. No abstract available.

PMID:
23043533
14.

Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.

Braun-Moscovici Y, Markovits D, Rozin A, Toledano K, Nahir AM, Balbir-Gurman A.

Isr Med Assoc J. 2008 Apr;10(4):277-81.

15.

Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study.

Genevay S, Finckh A, Ciurea A, Chamot AM, Kyburz D, Gabay C; Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis..

Arthritis Rheum. 2007 May 15;57(4):679-85.

16.

Anti-TNF-alpha agents are less effective for the treatment of rheumatoid arthritis in current smokers.

Abhishek A, Butt S, Gadsby K, Zhang W, Deighton CM.

J Clin Rheumatol. 2010 Jan;16(1):15-8. doi: 10.1097/RHU.0b013e3181ca4a2a.

PMID:
20051749
17.

Clinical significance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.

Cañete JD, Celis R, Moll C, Izquierdo E, Marsal S, Sanmartí R, Palacín A, Lora D, de la Cruz J, Pablos JL.

Ann Rheum Dis. 2009 May;68(5):751-6. doi: 10.1136/ard.2008.089284. Epub 2008 May 21.

PMID:
18495732
18.

Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis.

Barrera P, van der Maas A, van Ede AE, Kiemeney BA, Laan RF, van de Putte LB, van Riel PL.

Rheumatology (Oxford). 2002 Apr;41(4):430-9.

PMID:
11961174
19.

Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function.

Ernestam S, Hafström I, Werner S, Carlström K, Tengstrand B.

J Rheumatol. 2007 Jul;34(7):1451-8. Epub 2007 May 1.

PMID:
17477470
20.

Successful treatment of rheumatoid arthritis is associated with a reduction in synovial membrane cytokines and cell adhesion molecule expression.

Smith MD, Slavotinek J, Au V, Weedon H, Parker A, Coleman M, Roberts-Thomson PJ, Ahern MJ.

Rheumatology (Oxford). 2001 Sep;40(9):965-77.

PMID:
11561106

Supplemental Content

Support Center